We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Information-Rich Drug Discovery Enabled by Next-Generation Multiplexing SPR

Detailed validation is key in successful drug development. Surface plasmon resonance (SPR) offers a label-free, direct-binding analysis that brings additional insights into drug kinetics compared to established functional assays.

SPR gives detailed information on affinity, complex half-life, thermodynamic constants and mode-of-action of potential candidates.

In this webinar, you’ll discover how SPR can be multiplexed and automated to enable high-throughput, data-rich drug candidate screening against multiple target proteins. 

Attend this webinar to discover:

  • The relevance of kinetics and SPR for your drug development project
  • The value of multiplexing assays for drug development
  • Bruker’s newest Triceratops SPR #64, its flexibility and throughput in drug discovery and development pipelines
Dr. Cyrill George Brunner
Dr. Cyrill George Brunner
Senior Application Specialist
Bruker Daltonics
Brought to you by
Now Available on Demand!
Information you provide will be shared with the sponsors for this content. Technology Networks or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.
Want to invite a colleague?

Click the button below to begin inviting a colleague to this Webinar